Stories

UK tobacco policy risks burying its head in the ash if it ignores the role safer nicotine products can play in reducing smoking. Cigarettes remain the most harmful option, yet restrictions on vaping, pouches and other smoke-free alternatives may make switching less attractive for adult smokers. Harm reduction does not mean denying risk — it means recognising that not all risks are equal. Public health should focus on moving people away from combustion, not making safer choices harder.

Cutting tobacco excise alone will not fix illicit trade if the wider policy environment still drives consumers towards unregulated markets. Illegal tobacco is shaped by organised supply chains, enforcement gaps, high demand and the lack of realistic alternatives for smokers. A stronger response should combine targeted enforcement with harm reduction, accurate risk communication and legal access to lower-risk nicotine products. The goal should be reducing smoking-related harm, not relying on tax policy alone.

Prohibition carries health, wellbeing and ethical costs that are often overlooked. When safer nicotine products are restricted, people may be pushed towards cigarettes, illicit markets or unsafe supply chains. Harm reduction offers a more humane approach by reducing risk without demanding perfect abstinence. Public health should protect people in the real world, not punish them for using nicotine.

The evidence from real-world nicotine policy is already in: prohibition and excessive restriction do not eliminate demand, they change where demand goes. Countries that preserve access to safer alternatives see more realistic routes away from smoking, while those that ban or overtax them often strengthen illicit markets. The lesson is clear — regulation should be measured by outcomes, not intentions. It is time for nicotine policy to follow the evidence.

Palau’s proposal for a global nicotine ban raises serious concerns about proportionality, evidence and unintended consequences. Treating smoke-free nicotine products like illicit drugs ignores the major difference between dependence and the harms caused by combustion. Prohibition would not remove demand — it would push consumers towards illegal markets while cigarettes remain the most dangerous option. Global nicotine policy should reduce harm, not repeat the failures of the war on drugs.

Mongolia’s experience shows why tobacco harm reduction must include the voices of advocates working closest to smokers. In countries where smoking rates remain high and cessation support is limited, lower-risk nicotine alternatives can offer a practical route away from combustible tobacco. Ignoring local realities risks leaving smokers with cigarettes as the easiest option. Public health policy should listen to people on the ground and support solutions that reduce harm in real-world conditions.

The UK Tobacco and Vapes Bill will reshape how vaping products are sold, marketed and regulated. While youth protection remains important, broad restrictions on flavours, packaging and promotion could also affect adult smokers who rely on vaping to move away from cigarettes. For vapers, the key issue is whether regulation targets irresponsible sales without weakening access to lower-risk alternatives. Good policy should protect young people while preserving vaping’s role in reducing smoking-related harm.

Public records from California raise troubling questions about how tobacco “endgame” policies are being advanced. When health agencies and funded partners coordinate messaging, polling and local campaigns behind the scenes, public consultation risks becoming political theatre rather than genuine debate. Tobacco policy should be transparent, evidence-based and accountable to the communities it affects. Public health loses trust when outcomes appear to be managed before the public has been heard.

The lack of urgency in US nicotine regulation is leaving adult smokers with fewer legal, lower-risk options while cigarettes remain widely available. Delays, uncertainty and uneven enforcement weaken the regulated market and create space for illicit products to grow. Harm reduction cannot work if safer alternatives are trapped in regulatory limbo. Public health should move faster to support products that help people leave combustion behind.

The Philippines health controversy is raising wider questions about transparency, influence and trust in tobacco policy. Harm reduction advocates warn that international pressure from the WHO and Bloomberg-linked networks may be shaping national decisions in ways that overlook local evidence, consumer needs and lower-risk alternatives. Public health policy should be accountable to the people it affects, not driven by opaque influence campaigns. Trust depends on open debate, clear evidence and regulation that reflects real-world outcomes.